Cervical smear companies AutoCyte and NeoPath merge in a $100 million deal
This article was originally published in Clinica
Executive Summary
In a further consolidation of the automated and monolayer cervical cytology markets, AutoCyte and NeoPath are to merge in a deal valued at around $100 million.